Canagliflozin was the first SGLT2 inhibitor to be approved by the FDA, and its approval took place in January, 2013. However, data on dapagliflozin had been presented to the FDA for review as early as July, 2011, but its approval was delayed until January 2014, mostly because of concerns about increased risks for bladder and breast cancer.